• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and experimental allergy : >The performance of a component-based allergen microarray for the diagnosis of kiwifruit allergy.
【24h】

The performance of a component-based allergen microarray for the diagnosis of kiwifruit allergy.

机译：基于成分的过敏原微阵列诊断奇异果过敏的性能。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Allergy to kiwifruit is increasingly reported across Europe. Currently, the reliability of its diagnosis by the measurement of allergen-specific IgE with extracts or by skin testing with fresh fruits is unsatisfying. OBJECTIVE: To evaluate the usefulness of a component-based allergen microarray for the diagnosis of kiwifruit allergy in a large group of patients. METHODS: With an allergen microarray, we measured specific IgE and IgG4 levels to a panel of nine kiwifruit allergens in sera of 237 individuals with kiwifruit allergy. Sera from 198 allergic patients without kiwifruit allergy served as controls. Furthermore, we determined the extent of sensitization to latex. RESULTS: The panel of kiwifruit allergens showed a diagnostic sensitivity of 66%, a specificity of 56% and a positive predictive value of 73%. Sera from kiwifruit-allergic patients contained significantly more frequently Act d 1-specific IgE than sera from control patients. Furthermore, 51% of the positive sera contained IgE directed to a single allergen, namely Act d 1 (45%), Act d 9 (27%) or Act d 7 (13%). Within the control group, 36% sera recognized a single allergen. Out of those, 48% were positive to the cross-reactive glycoallergen Act d 7, 43% to the profilin Act d 9 and only 5% to Act d 1. Allergen-specific IgG4 levels did not differ between kiwifruit-allergic and -tolerant patients. Kiwifruit- and latex-allergic patients contained Hev b 11-specific IgE significantly more frequently than latex-allergic patients without kiwifruit allergy. CONCLUSIONS: Act d 1 can be considered a marker allergen for genuine sensitization to kiwifruit. We demonstrated that a component-based kiwifruit allergen microarray would improve the prognostic value of in vitro diagnostic tests.
机译：背景：在欧洲，越来越多的人对猕猴桃过敏。当前，通过用提取物测量过敏原特异性IgE或通过用新鲜水果进行皮肤测试来诊断其可靠性尚不令人满意。目的：评估基于组件的过敏原微阵列在大批患者中诊断奇异果过敏的有效性。方法：使用过敏原微阵列，我们测量了237名猕猴桃过敏者血清中九种猕猴桃过敏原的特异性IgE和IgG4水平。来自198名没有猕猴桃过敏的过敏患者的血清作为对照。此外，我们确定了对乳胶的敏感程度。结果：猕猴桃过敏原组显示出66％的诊断敏感性，56％的特异性和73％的阳性预测值。奇异果过敏患者的血清比对照组患者的血清含有更多的Act d 1特异性IgE。此外，阳性血清中有51％包含针对单一过敏原的IgE，即d1法（45％），d 9法（27％）或d7法（13％）。在对照组中，36％的血清识别单一过敏原。其中，对交叉反应性糖过敏原法第7 d阳性的有48％，对脯氨酸蛋白法d 9阳性的有43％，对d Act 1仅有5％的过敏原。猕猴桃过敏和耐受的过敏原特异性IgG4水平没有差异。耐心。猕猴桃和乳胶过敏的患者含有Hev b 11特异性IgE的频率明显高于没有猕猴桃过敏的乳胶过敏的患者。结论：Act d 1可被认为是对猕猴桃真正致敏的标志物过敏原。我们证明了基于成分的奇异果过敏原微阵列将改善体外诊断测试的预后价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号